PRONEUROGEN
ProNeurogen is an early-stage biotech company. It is developing novel drug therapeutics to prevent and treat inflammation-induce brain disorders, including: pain, cognitive impairment, memory loss and dementia. ProNeurogen's novel drug technology is based on R&D conducted at the University of Arizona.
PRONEUROGEN
Social Links:
Industry:
Biotechnology
Founded:
2013-01-01
Address:
Tucson, Arizona, United States
Country:
United States
Website Url:
http://www.proneurogen.com
Total Employee:
1+
Status:
Active
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Google Font API Content Delivery Network Organization Schema Pound Sterling Typekit LocalBusiness Schema Squarespace
Similar Organizations
MouSensor
MouSensor is an early-stage biotech company.
Polgenix
Polgenix is a small biotech company.
T-Cypher Bio
T-Cypher Bio is an early-stage biotechnology company.
Vivo Biosciences
Vivo Biosciences is an early stage biotech company.
Official Site Inspections
http://www.proneurogen.com
- Host name: 198.49.23.144
- IP address: 198.49.23.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "ProNeurogen"
About — ProNeurogen
Vision: To be the global leader in protecting brain health of millions by developing life-changing therapies to treat cognitive impairment associated with neurodegenerative diseases. …See details»
ProNeurogen - Crunchbase Company Profile & Funding
ProNeurogen is an early-stage biotech company. It is developing novel drug therapeutics to prevent and treat inflammation-induce brain disorders, including: pain, cognitive impairment, …See details»
Leadership — ProNeurogen
Tamara Crockett, Esq Director and IP Advisor. Tamara brings a wealth of experience in technology commercialization, intellectual property, technology transfer, start-ups and early stage commercialization to this project.See details»
PRONEUROGEN INC Overview | SignalHire Company Profile
Organization Website: proneurogen.com : PRONEUROGEN INC industries Pharma: Headquarters Location: 1970 N Wentworth Rd, Tucson, Arizona, US 1970 N Wentworth ...See details»
ProNeurogen - Company Profile - Tracxn
Nov 27, 2024 ProNeurogen - Developer of therapeutics to treat vascular dementia and neuropathic pain. Founded by Meredith Hay in the year 2013. ProNeurogen has 545 competitors.See details»
Proneurogen, Inc. Company Profile | Tucson, AZ | Competitors ...
Find company research, competitor information, contact details & financial data for Proneurogen, Inc. of Tucson, AZ. Get the latest business insights from Dun & Bradstreet.See details»
ProNeurogen - Overview, News & Similar companies - ZoomInfo
ProNeurogen is an early-stage biotech company. It is developing novel drug therapeutics to prevent and treat inflammation-induce brain disorders, including: pain, cognitive impairment, …See details»
ProNeurogen Company Profile | Management and Employees List
Find contact information for ProNeurogen. Learn about their Business Services market share, competitors, and ProNeurogen's email format.See details»
PRONEUROGEN INC - Company Profile & Staff Directory
ProNeurogen is an early-stage biotech company. It is developing novel drug therapeutics to prevent and treat inflammation-induce brain disorders, including: pain, cognitive impairment, …See details»
PRONEUROGEN INC Financial Overview, Employee Count, and …
ProNeurogen is an early-stage biotech company. It is developing novel drug therapeutics to prevent and treat inflammation-induce brain disorders, including: pain, cognitive impairment, …See details»
ProNeurogen - Products, Competitors, Financials, Employees ...
ProNeurogen is an early-stage biotech company focused on developing novel peptides for cognitive and memory deficits due to brain inflammation. The company's main offerings …See details»
Copy of About — ProNeurogen
Our Mission: To develop drug therapies for preventing and treating cognitive impairment and pain caused by inflammation.. Brain Inflammation: Pain, cognitive impairment and memory loss …See details»
Proneurogen Inc | www.inknowvation.com
ProNeurogen's PNA-5 drug candidate improves the effects of the Angiotensin-(1-7) peptide by moving it across the blood-brain-barrier, increasing its half-life and improving its stability. …See details»
Proneurogen, Inc - VentureRadar
ProNeurogen Peptides are Selective Mas Receptor Agonists: Ang-(1-7) is a member of the Renin-Angiotensin family; Binds to small GPCR Mas receptor; Ang-(1–7) activation of Mas results in …See details»
PNA5 targets Parkinson’s cognitive symptoms, may slow decline
Nov 26, 2024 50% to 70% of later-stage patients have cognitive symptoms. One study researcher, Meredith Hay, PhD — a professor of physiology at the University of Arizona and …See details»
PIPELINE — ProNeurogen
Proneurogen therapeutic platform pipeline we are developing a platform of drug candidates that have the potential to improve patient’s lives by targeting the underlying causes of vascular and …See details»
PNA5 - Drug Targets, Indications, Patents - Synapse - Patsnap
Abstract Background Decreased cerebral blood flow and systemic inflammation during heart failure (HF) increase the risk for vascular contributions to cognitive impairment and dementia …See details»
News — ProNeurogen
Proneurogen neuroprotective peptide ind application for pna1 gets go-ahead from fda for phase ii study in cardiac bypass patients. aug 2015. proneurogen signs exclusive license with the …See details»
What is Vascular Dementia — ProNeurogen
ProNeurogen Therapeutics’ novel peptides inhibit this inflammatory cascade and improve brain blood flow. These peptides are designed to significantly improve serum half-life and penetrate …See details»